<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-10-13</article-id><article-id pub-id-type="pmid">19216768</article-id><article-id pub-id-type="doi">10.1186/1471-2350-10-13</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evaluating the association of common <italic>APOA2 </italic>variants with type 2 diabetes</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Duesing</surname><given-names>Konsta</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>k.duesing@imperial.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Charpentier</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Guillaume.Charpentier@ch-sud-francilien.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Marre</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>michel.marre@bch.ap-hop-paris.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tichet</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>jean.tichet@irsa.asso.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hercberg</surname><given-names>Serge</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>s.hercberg@uren.smbh.univ-paris13.fr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Balkau</surname><given-names>Beverley</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>balkau@vjf.inserm.fr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Froguel</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I8">8</xref><email>p.froguel@imperial.ac.uk</email></contrib><contrib id="A8" corresp="yes" contrib-type="author"><name><surname>Gibson</surname><given-names>Fernando</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fernando.gibson@imperial.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Genomic Medicine, Imperial College London, Hammersmith Campus, Du Cane Rd, London, W12 0NN, UK</aff><aff id="I2"><label>2</label>Endocrinology-Diabetology Unit, Corbeil Hospital, Corbeil, France</aff><aff id="I3"><label>3</label>Endocrinology-Diabetology, Bichat Hospital, Paris, France</aff><aff id="I4"><label>4</label>INSERM U695, Paris, France</aff><aff id="I5"><label>5</label>Institut R&#x000e9;gional Pour la Sant&#x000e9;, Tours, France</aff><aff id="I6"><label>6</label>Scientific and Technical Institute of Nutrition and Food (ISTNA-CNAM), Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (INSERM) U557, INRA U1125, Paris, France</aff><aff id="I7"><label>7</label>INSERM U780-IFR69, Villejuif, France</aff><aff id="I8"><label>8</label>CNRS 8090, Institut de Biologie de Lille, Institut Pasteur, CHU Lille, France</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>13</day><month>2</month><year>2009</year></pub-date><volume>10</volume><fpage>13</fpage><lpage>13</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/13"/><history><date date-type="received"><day>10</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Duesing et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Duesing et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Duesing Konsta k.duesing@imperial.ac.uk </dc:author><dc:title> Evaluating the association of common APOA2 variants with type 2 diabetes </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 10(1): 13-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2009)10:1&#x0003c;13&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p><italic>APOA2 </italic>is a positional and biological candidate gene for type 2 diabetes at the chromosome 1q21-q24 susceptibility locus. The aim of this study was to examine if HapMap phase II tag SNPs in <italic>APOA2 </italic>are associated with type 2 diabetes and quantitative traits in French Caucasian subjects.</p></sec><sec sec-type="methods"><title>Methods</title><p>We genotyped the three HapMap phase II tagging SNPs (rs6413453, rs5085 and rs5082) required to capture the common variation spanning the <italic>APOA2 </italic>locus in our type 2 diabetes case-control cohort comprising 3,093 French Caucasian subjects. The association between these variants and quantitative traits was also examined in the normoglycaemic adults of the control cohort. In addition, meta-analysis of publicly available whole genome association data was performed.</p></sec><sec><title>Results</title><p>None of the <italic>APOA2 </italic>tag SNPs were associated with type 2 diabetes in the French Caucasian case-control cohort (rs6413453, <italic>P </italic>= 0.619; rs5085, <italic>P </italic>= 0.245; rs5082, <italic>P </italic>= 0.591). However, rs5082 was marginally associated with total cholesterol levels (<italic>P </italic>= 0.026) and waist-to-hip ratio (<italic>P </italic>= 0.029). The meta-analysis of data from 12,387 subjects confirmed our finding that common variation at the <italic>APOA2 </italic>locus is not associated with type 2 diabetes.</p></sec><sec><title>Conclusion</title><p>The available data does not support a role for common variants in <italic>APOA2 </italic>on type 2 diabetes susceptibility or related quantitative traits in Northern Europeans.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The <italic>APOA2 </italic>gene is located at chromosome 1q23.3, within the 1-LOD support interval of several genome-wide linkage scans for type 2 diabetes [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. The peak of linkage in the French and Utah Caucasian genome-wide linkage scans was defined by the <italic>APOA2 </italic>intragenic microsatellite D1SAPO2 [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. <italic>APOA2 </italic>encodes the apolipoprotein (apo) A-II, the second most abundant protein of the high-density lipoprotein (HDL) particles [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Transgenic mice overexpressing human <italic>APOA2 </italic>on a standard chow diet displayed lipid profiles similar to that seen in human type 2 diabetes [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, plasma human apoA-II levels were positively correlated with blood glucose levels and these animals displayed impaired glucose tolerance [<xref ref-type="bibr" rid="B7">7</xref>]. In the human HepG2 cell line and in rat primary hepatocytes, transcription of the human <italic>APOA2 </italic>transgene was upregulated by glucose in a <italic>HNF-4&#x000e1;</italic>-dependent fashion, whereas in streptozotocin-induced diabetic rats <italic>Apoa2 </italic>mRNA levels were not affected [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Overexpression of mouse <italic>Apoa2 </italic>contrastingly resulted in elevated levels of HDL and fasting blood glucose levels that were not significantly different from normal [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. However, these mice appeared to be in a state of insulin resistance exhibiting two-fold raised plasma insulin levels, decreased triglyceride hydrolysis and increased fat deposition in adipose tissue, as well as delayed glucose clearance due to slower uptake in skeletal muscle [<xref ref-type="bibr" rid="B8">8</xref>]. Taken together, these findings point to a primary lipoprotein disturbance causing the development of several features of insulin resistance.</p><p>On the other hand, homozygous <italic>Apoa2 </italic>null-mice had HDL level reductions of 70%, as well as lower free fatty acid, glucose and insulin levels, suggesting they may be insulin hypersensitive [<xref ref-type="bibr" rid="B11">11</xref>].</p><sec><title>Previous genetic analysis of <italic>APOA2 </italic>in type 2 diabetes</title><p>Elbein and colleagues tested four <italic>APOA2 </italic>variants for association with T2D by TDT in 698 family members and in a very small case-control cohort of 247 subjects [<xref ref-type="bibr" rid="B12">12</xref>]. None of the SNPs exhibited association with T2D in the case-control cohort, nor were any of the SNP alleles over-transmitted in the TDT analysis. Certain microsatellite alleles, however, indicated a trend for excess transmission to diabetic patients and marginal association with triglyceride levels, FFA and fasting glucose, as well as first phase insulin response and insulin deposition index in model analysis [<xref ref-type="bibr" rid="B12">12</xref>].</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Case-control subjects</title><p>All subjects were of French Caucasian ancestry. Individuals identified by Sladek <italic>et al. </italic>[<xref ref-type="bibr" rid="B13">13</xref>] to lie outside the HapMap CEU ancestry cluster were excluded from the study. Type 2 diabetic case subjects were known diabetic patients receiving treatment for the condition. Normoglycaemic control subjects were selected to have a fasting blood glucose concentration &#x0003c;6.1 mM [<xref ref-type="bibr" rid="B14">14</xref>]. Case subjects were composed of: (i) 372 probands from diabetic families [<xref ref-type="bibr" rid="B3">3</xref>], recruited in Lille; and (ii) 1083 patients with a family history of T2D recruited at the Corbeil-Essonne Hospital. Control subjects were composed of: (i) 353 normoglycaemic parents from T2D families; (ii) 543 subjects from the SUVIMAX (Supplementation en Vitamines et Min&#x000e9;raux Antioxidant) prospective population-based cohort study [<xref ref-type="bibr" rid="B15">15</xref>]; and (iii) 742 subjects selected from the DESIR (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort, a large prospective study of insulin resistance in French subjects [<xref ref-type="bibr" rid="B16">16</xref>]. Informed consent was obtained from all subjects and the study was approved by the local ethics committees.</p></sec><sec><title>Statistical power</title><p>The case-control cohort comprised 1,455 type 2 diabetic subjects (age, 60 &#x000b1; 12 years; BMI, 29.0 &#x000b1; 6.0 kg/m<sup>2</sup>; male/female, 56:44%) and 1,638 normoglycaemic subjects (age, 54 &#x000b1; 13 years; BMI, 24.1 &#x000b1; 3.3 kg/m<sup>2</sup>; male/female, 43:57%). At &#x003b1; = 0.05, this sample size provided 91% power [<xref ref-type="bibr" rid="B17">17</xref>] to detect a type 2 diabetes susceptibility variant, assuming an allele frequency of 0.20, a disease prevalence of 0.1 and a heterozygote relative risk of 1.2 (multiplicative model).</p></sec><sec><title><italic>APOA2 </italic>tag SNP selection</title><p>The genomic target region for tag SNP selection extended across the 3 kb NCBI36 <italic>APOA2 </italic>locus (chr1:159,458,001..159,461,000). A total of three HapMap phase II pairwise tagging SNPs (rs6413453, rs5085 and rs5082) were sufficient to tag the common variation across the <italic>APOA2 </italic>locus (HapMap Data Release 22/Apr07) with r<sup>2 </sup>and minor allele frequency (MAF) thresholds of 0.9 and 0.05, respectively.</p></sec><sec><title>SNP genotyping</title><p>Genotyping was performed with the Sequenom MassARRAY iPLEX system [<xref ref-type="bibr" rid="B18">18</xref>]. SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using chi-squared analysis. Quality control: all genotyped SNPs exhibited a call rate &#x0003e;99% and a Hardy-Weinberg <italic>P </italic>&#x0003e; 0.05, with well defined genotype clusters. In total, 19 case and 42 control subjects (1.97% of the total sample size) consistently failed genotyping and were removed from further analysis.</p></sec><sec><title>Statistical analyses</title><p>To test for association of <italic>APOA2 </italic>SNPs with type 2 diabetes, chi-squared analysis of allele and genotype counts was performed. Pairwise SNP linkage disequilibrium (LD) values were calculated from the genotype data of the control cohort with Haploview (4.0) [<xref ref-type="bibr" rid="B19">19</xref>]. Quantitative anthropomorphic phenotypes, body mass index (BMI), weight and waist-hip ratio (WHR), as well as fasting serum levels of glucose, insulin, triacylglycerol (TG), total and high-density lipoprotein (HDL)-cholesterol, apolipoprotein A-I (APOA1) and apolipoprotein B (APOB), measured in 1,539 normoglycaemic subjects from the control cohort, were log transformed and adjusted for age, sex and BMI, as appropriate. SNPs were tested for association with adjusted quantitative traits using SPSS 15.0 with the ANOVA test under a codominant model. Quantitative trait association p-values are presented uncorrected for multiple testing. Combined analysis of association datasets was carried out by pooling of log-transformed odds ratios with the inverse variance method for the fixed-effects and random-effects models. The DIAGRAM [<xref ref-type="bibr" rid="B20">20</xref>] data included a sib-ship component from the DGI GWAS [<xref ref-type="bibr" rid="B21">21</xref>]; however, due to uncertainties about controlling for the effects of the relatedness of part of the study sample, we excluded these subjects and obtained data solely for unrelated subjects from the authors (E. Zeggini, personal communication, 23/04/2008). Inter-study heterogeneity was assessed with Cochran's <italic>Q </italic>statistic and the I<sup>2 </sup>metric [<xref ref-type="bibr" rid="B22">22</xref>]. These calculations were performed using R (2.5.1) statistical software [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec></sec><sec><title>Results</title><p>None of the three genotyped <italic>APOA2 </italic>tag SNPs showed evidence for association (<italic>P </italic>&#x0003c; 0.05) with type 2 diabetes in this French Caucasian cohort (Table <xref ref-type="table" rid="T1">1</xref>; genotype counts see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Additional table 1). This finding is in agreement with the French GWAS [<xref ref-type="bibr" rid="B13">13</xref>], as well as a recent meta-analysis [<xref ref-type="bibr" rid="B20">20</xref>] of the DGI [<xref ref-type="bibr" rid="B21">21</xref>], FUSION [<xref ref-type="bibr" rid="B24">24</xref>] and WTCCC [<xref ref-type="bibr" rid="B25">25</xref>] genome-wide association studies.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Association of <italic>APOA2 </italic>SNPs with type 2 diabetes.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>SNP</bold></td><td align="left"><bold>Allele</bold><sup>a</sup></td><td align="left"><bold>Chr Position (NCBI36)</bold></td><td align="left"><bold>Gene Region</bold></td><td align="left"><bold>N subjects</bold></td><td></td><td align="left"><bold>Allele 1 (%)</bold></td><td align="left"><bold>Allele 2 (%)</bold></td><td align="left"><bold>Call Rate</bold></td><td align="left"><bold>OR (95% CI)</bold></td><td align="left"><bold><italic>P</italic></bold></td><td align="left"><bold>DIAGRAM GWAS-MA</bold><break/><bold><italic>P</italic></bold><sup>#</sup></td></tr></thead><tbody><tr><td align="left"><bold>rs6413453</bold></td><td align="left">C/T</td><td align="left">159458940</td><td align="left">INTRONIC</td><td align="left">T2D</td><td align="left">1414</td><td align="left">2523 (89)</td><td align="left">299 (11)</td><td align="left">&#x0003e;99%</td><td align="left">1.04 (0.89&#x02013;1.23)</td><td align="left">0.619</td><td align="left">0.808<sup>$</sup></td></tr><tr><td></td><td></td><td></td><td></td><td align="left">NG</td><td align="left">1581</td><td align="left">2809 (89)</td><td align="left">347 (11)</td><td align="left">&#x0003e;99%</td><td></td><td></td><td></td></tr><tr><td align="left"><bold>rs5085</bold></td><td align="left">G/C</td><td align="left">159459135</td><td align="left">INTRONIC</td><td align="left">T2D</td><td align="left">1441</td><td align="left">2304 (80)</td><td align="left">568 (20)</td><td align="left">100%</td><td align="left">1.08 (0.95&#x02013;1.23)</td><td align="left">0.245</td><td align="left">0.225</td></tr><tr><td></td><td></td><td></td><td></td><td align="left">NG</td><td align="left">1596</td><td align="left">2595 (81)</td><td align="left">593 (19)</td><td align="left">&#x0003e;99%</td><td></td><td></td><td></td></tr><tr><td align="left"><bold>rs5082</bold></td><td align="left">T/C</td><td align="left">159460307</td><td align="left">UPSTREAM</td><td align="left">T2D</td><td align="left">1442</td><td align="left">1796 (63)</td><td align="left">1066 (37)</td><td align="left">&#x0003e;99%</td><td align="left">1.03 (0.93&#x02013;1.14)</td><td align="left">0.591</td><td align="left">0.408<sup>$</sup></td></tr><tr><td></td><td></td><td></td><td></td><td align="left">NG</td><td align="left">1603</td><td align="left">1963 (62)</td><td align="left">1199 (38)</td><td align="left">&#x0003e;99%</td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>SNP alleles are shown as major/minor. <sup>#</sup>Please refer to Methods section for details. <sup>$</sup>Imputed SNPs.</p></table-wrap-foot></table-wrap><sec><title>Quantitative trait associations</title><p>The <italic>APOA2 </italic>promoter SNP rs5082 was marginally associated with total cholesterol levels (<italic>P </italic>= 0.026) and waist-to-hip ratio (<italic>P </italic>= 0.029) (Table <xref ref-type="table" rid="T2">2</xref>), and both associations exhibited a linear increase of the value of the quantitative phenotype from the common homozygote to the rare homozygote allele carriers (Table <xref ref-type="table" rid="T3">3</xref>). The intronic variant rs6413453 was marginally associated with weight (<italic>P </italic>= 0.049), but given the small number of homozygote carriers of the minor allele (n = 13), it is likely that this is a spurious result (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association of <italic>APOA2 </italic>SNPs with quantitative traits in French Caucasian control subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Trait</td><td align="left">n</td><td align="left">Mean &#x000b1; SD</td><td align="left">rs6413453</td><td align="left">rs5085</td><td align="left">rs5082</td></tr></thead><tbody><tr><td align="left">BMI</td><td align="left">1437</td><td align="left">24.37 &#x000b1; 0.09</td><td align="left">0.682</td><td align="left">0.806</td><td align="left">0.075</td></tr><tr><td align="left">GLY0</td><td align="left">1400</td><td align="left">5.21 &#x000b1; 0.02</td><td align="left">0.820</td><td align="left">0.401</td><td align="left">0.687</td></tr><tr><td align="left">INS0</td><td align="left">843</td><td align="left">50.01 &#x000b1; 1.17</td><td align="left">0.632</td><td align="left">0.280</td><td align="left">0.450</td></tr><tr><td align="left">TG</td><td align="left">1311</td><td align="left">1.12 &#x000b1; 0.02</td><td align="left">0.178</td><td align="left">0.713</td><td align="left">0.404</td></tr><tr><td align="left">CHOL_TOT</td><td align="left">1318</td><td align="left">5.94 &#x000b1; 0.03</td><td align="left">0.509</td><td align="left">0.249</td><td align="left"><bold>0.026</bold></td></tr><tr><td align="left">HDL</td><td align="left">792</td><td align="left">1.58 &#x000b1; 0.01</td><td align="left">0.658</td><td align="left">0.171</td><td align="left">0.913</td></tr><tr><td align="left">APOA1</td><td align="left">1427</td><td align="left">1.68 &#x000b1; 0.01</td><td align="left">0.169</td><td align="left">0.219</td><td align="left">0.778</td></tr><tr><td align="left">APOB</td><td align="left">1425</td><td align="left">1.1 &#x000b1; 0.01</td><td align="left">0.829</td><td align="left">0.518</td><td align="left">0.121</td></tr><tr><td align="left">WEIGHT</td><td align="left">1191</td><td align="left">66.14 &#x000b1; 0.33</td><td align="left"><bold>0.049</bold></td><td align="left">0.389</td><td align="left">0.603</td></tr><tr><td align="left">WHR</td><td align="left">1164</td><td align="left">0.84 &#x000b1; 0.00</td><td align="left">0.932</td><td align="left">0.341</td><td align="left"><bold>0.029</bold></td></tr></tbody></table><table-wrap-foot><p>Association testing of <italic>APOA2 </italic>SNPs was carried out by ANOVA using SPSS (15.0). All traits were log transformed prior to correction for age, sex and BMI by linear regression, as appropriate. Trait means are presented anti-logged and <italic>P</italic>-values are reported without correction for multiple testing. BMI: body mass index; GLY0: fasting glucose; INS0: fasting insulin; TG: triacylglycerol; CHOL_TOT: total cholesterol; HDL: high-density lipoprotein-cholesterol; APOA1: apolipoprotein A-I; APOB: apolipoprotein B; WHR: waist-hip ratio.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Distribution of quantitative trait values grouped by genotype for significant association results.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="4">Genotypes (n)</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td align="left"><underline>rs5082</underline></td><td align="left">TT</td><td align="left">TC</td><td align="left">CC</td><td align="left"><italic>P</italic></td></tr><tr><td align="left">CHOL_TOT (mM)</td><td align="left">5.88 &#x000b1; 0.97<break/>(506)</td><td align="left">5.95 &#x000b1; 0.92<break/>(600)</td><td align="left">6.10 &#x000b1; 1.01<break/>(185)</td><td align="left">0.026</td></tr><tr><td align="left">WHR</td><td align="left">0.841 &#x000b1; 0.091<break/>(455)</td><td align="left">0.843 &#x000b1; 0.092<break/>(529)</td><td align="left">0.855 &#x000b1; 0.092<break/>(153)</td><td align="left">0.029</td></tr></thead><tbody><tr><td align="left"><underline>rs6413453</underline></td><td align="left">CC</td><td align="left">CT</td><td align="left">TT</td><td></td></tr><tr><td align="left">WEIGHT (kg)</td><td align="left">66.02 &#x000b1; 11.60<break/>(905)</td><td align="left">66.10 &#x000b1; 11.52<break/>(229)</td><td align="left">70.38 &#x000b1; 8.63<break/>(13)</td><td align="left">0.049</td></tr></tbody></table><table-wrap-foot><p>Association testing was carried out by ANOVA comparison of trait means between genotype groups using SPSS (15.0). All traits were transformed prior to correction for age, sex and BMI by linear regression. The quantitative trait values displayed are the anti-logged trait means &#x000b1; SD.</p></table-wrap-foot></table-wrap></sec><sec><title>Linkage disequilibrium structure of the <italic>APOA2 </italic>genomic locus</title><p>The structure of linkage disequilibrium across the three tag SNPs studied was consistent with HapMap phase II data. The levels of intermarker LD (r<sup>2</sup>) were negligible for the <italic>APOA2 </italic>locus (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Additional table 2). Therefore, no haplotype analysis was performed for <italic>APOA2 </italic>variants.</p></sec><sec><title>Meta-analysis of <italic>APOA2 </italic>variants</title><p>Meta-analysis combining publicly available data with our current study confirmed in over 12,000 subjects that none of the <italic>APOA2 </italic>tag SNPs were associated with type 2 diabetes (Additional files <xref ref-type="supplementary-material" rid="S2">2</xref>, <xref ref-type="supplementary-material" rid="S3">3</xref>, <xref ref-type="supplementary-material" rid="S4">4</xref>) and there appeared to be no study heterogeneity (Cochran's <italic>Q</italic>: <italic>P </italic>&#x0003e; 0.72; I<sup>2 </sup>= 0% for all variants). Consistent with the absence of inter-study heterogeneity the fixed and random effects models were identical for all three variants, therefore only the fixed effects are displayed.</p></sec></sec><sec><title>Discussion</title><p>The <italic>APOA2 </italic>gene appeared to be a highly plausible candidate gene for type 2 diabetes susceptibility. In addition to defining the peak of linkage at chromosome 1q in French and Utah Caucasian families, <italic>APOA2 </italic>is the second most abundant lipoprotein component of HDL-cholesterol and has been implicated in the regulation of lipid metabolism and insulin sensitivity.</p><p>Three HapMap phase II tag SNPs suffice to cover the common variation spanning <italic>APOA2 </italic>and genotyping of these variants demonstrated no association with type 2 diabetes. However, we cannot rule out the possibilities that distal common variants or rare <italic>APOA2 </italic>variants may be associated with type 2 diabetes. The quantitative trait association for the <italic>APOA2 </italic>variant rs5082 with total cholesterol levels was consistent with the physiological role of apoA-II; however, the strength of the association was marginal, as were the remaining, weaker associations with other continuous traits.</p><p>Meta-analysis of our data with DIAGRAM [<xref ref-type="bibr" rid="B20">20</xref>] consortium data, which was a mixture of directly genotyped and imputed SNPs (Table <xref ref-type="table" rid="T1">1</xref>), corroborated our findings of no association with type 2 diabetes. It was also welcome to note that the data from imputed SNPs were in this context indistinguishable from that of the directly genotyped variants.</p></sec><sec><title>Conclusion</title><p>Using a case-control cohort of over 3,000 subjects, we tested HapMap phase II tag SNPs that capture the common variation spanning the <italic>APOA2 </italic>genomic locus for association with type 2 diabetes, but failed to find any evidence supporting a contribution of this locus to type 2 diabetes susceptibility. This finding was confirmed in a combined analysis of more than 12,000 subjects.</p></sec><sec><title>Abbreviations</title><p>DGI: Diabetes Genetics Initiative; DIAGRAM: Diabetes Genetics Replication And Meta-analysis; FFA: free fatty acids; FUSION: Finland-United States Investigation of NIDDM Genetics; GWAS: Genome-wide association study; GWAS-MA: Genome-wide association study meta-analysis; WTCCC: Wellcome Trust Case-Control Consortium.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>KD participated in the design of the study, carried out the SNP genotyping, performed the analysis of the genotype data and drafted the manuscript. GC, MM, JT, SH and BB contributed to the design of the study. PF contributed to the study design and to drafting of the manuscript. FG contributed to the design of the study, the analysis of the genotype data and in drafting the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/10/13/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Additional tables 1 and 2.</bold> Word document containing a a table listing the genotype counts for each SNP and a tabular representation of the LD structure across the locus.</p></caption><media xlink:href="1471-2350-10-13-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Forest plot graphical summary of the meta-analysis for SNP rs6413453.</bold> Published data from the DIAGRAM [<xref ref-type="bibr" rid="B20">20</xref>] GWAS meta-analysis were combined with our data by pooling of log-transformed odds ratios with the inverse variance method using R (2.5.1) [<xref ref-type="bibr" rid="B23">23</xref>] software.</p></caption><media xlink:href="1471-2350-10-13-S2.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Forest plot graphical summary of the meta-analysis for SNP rs5085.</bold> Published data from the DIAGRAM [<xref ref-type="bibr" rid="B20">20</xref>] GWAS meta-analysis were combined with our data by pooling of log-transformed odds ratios with the inverse variance method using R (2.5.1) [<xref ref-type="bibr" rid="B23">23</xref>] software.</p></caption><media xlink:href="1471-2350-10-13-S3.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>Forest plot graphical summary of the meta-analysis for SNP rs5082.</bold> Published data from the DIAGRAM [<xref ref-type="bibr" rid="B20">20</xref>] GWAS meta-analysis were combined with our data by pooling of log-transformed odds ratios with the inverse variance method using R (2.5.1) [<xref ref-type="bibr" rid="B23">23</xref>] software.</p></caption><media xlink:href="1471-2350-10-13-S4.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by a Wellcome Trust University Award to F.G. (GR065414MF) and a Medical Research Council Program Grant to PF (G0000477). We thank the referees for critically appraising draft versions of the manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elbein</surname><given-names>SC</given-names></name><name><surname>Hoffman</surname><given-names>MD</given-names></name><name><surname>Teng</surname><given-names>K</given-names></name><name><surname>Leppert</surname><given-names>MF</given-names></name><name><surname>Hasstedt</surname><given-names>SJ</given-names></name></person-group><article-title>A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><fpage>1175</fpage><lpage>1182</lpage><pub-id pub-id-type="pmid">10331426</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.48.5.1175</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanson</surname><given-names>RL</given-names></name><name><surname>Ehm</surname><given-names>MG</given-names></name><name><surname>Pettitt</surname><given-names>DJ</given-names></name><name><surname>Prochazka</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>DB</given-names></name><name><surname>Timberlake</surname><given-names>D</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Kobes</surname><given-names>S</given-names></name><name><surname>Baier</surname><given-names>L</given-names></name><name><surname>Burns</surname><given-names>DK</given-names></name><name><surname>Almasy</surname><given-names>L</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Garvey</surname><given-names>WT</given-names></name><name><surname>Bennett</surname><given-names>PH</given-names></name><name><surname>Knowler</surname><given-names>WC</given-names></name></person-group><article-title>An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>1130</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">9758619</pub-id><pub-id pub-id-type="doi">10.1086/302061</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vionnet</surname><given-names>N</given-names></name><name><surname>Hani El</surname><given-names>H</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Gallina</surname><given-names>S</given-names></name><name><surname>Francke</surname><given-names>S</given-names></name><name><surname>Dotte</surname><given-names>S</given-names></name><name><surname>De Matos</surname><given-names>F</given-names></name><name><surname>Durand</surname><given-names>E</given-names></name><name><surname>Lepretre</surname><given-names>F</given-names></name><name><surname>Lecoeur</surname><given-names>C</given-names></name><name><surname>Gallina</surname><given-names>P</given-names></name><name><surname>Zekiri</surname><given-names>L</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24</article-title><source>Am J Hum Genet</source><year>2000</year><volume>67</volume><fpage>1470</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">11067779</pub-id><pub-id pub-id-type="doi">10.1086/316887</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borghini</surname><given-names>I</given-names></name><name><surname>James</surname><given-names>RW</given-names></name><name><surname>Blatter</surname><given-names>MC</given-names></name><name><surname>Pometta</surname><given-names>D</given-names></name></person-group><article-title>Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications</article-title><source>Biochim Biophys Acta</source><year>1991</year><volume>1083</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">1903658</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weisgraber</surname><given-names>KH</given-names></name><name><surname>Mahley</surname><given-names>RW</given-names></name></person-group><article-title>Apoprotein (E-A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction</article-title><source>J Biol Chem</source><year>1978</year><volume>253</volume><fpage>6281</fpage><lpage>6288</lpage><pub-id pub-id-type="pmid">210174</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boisfer</surname><given-names>E</given-names></name><name><surname>Lambert</surname><given-names>G</given-names></name><name><surname>Atger</surname><given-names>V</given-names></name><name><surname>Tran</surname><given-names>NQ</given-names></name><name><surname>Pastier</surname><given-names>D</given-names></name><name><surname>Benetollo</surname><given-names>C</given-names></name><name><surname>Trottier</surname><given-names>JF</given-names></name><name><surname>Beaucamps</surname><given-names>I</given-names></name><name><surname>Antonucci</surname><given-names>M</given-names></name><name><surname>Laplaud</surname><given-names>M</given-names></name><name><surname>Griglio</surname><given-names>S</given-names></name><name><surname>Chambaz</surname><given-names>J</given-names></name><name><surname>Kalopissis</surname><given-names>AD</given-names></name></person-group><article-title>Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>11564</fpage><lpage>11572</lpage><pub-id pub-id-type="pmid">10206963</pub-id><pub-id pub-id-type="doi">10.1074/jbc.274.17.11564</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauvaget</surname><given-names>D</given-names></name><name><surname>Chauffeton</surname><given-names>V</given-names></name><name><surname>Dugue-Pujol</surname><given-names>S</given-names></name><name><surname>Kalopissis</surname><given-names>AD</given-names></name><name><surname>Guillet-Deniau</surname><given-names>I</given-names></name><name><surname>Foufelle</surname><given-names>F</given-names></name><name><surname>Chambaz</surname><given-names>J</given-names></name><name><surname>Leturque</surname><given-names>A</given-names></name><name><surname>Cardot</surname><given-names>P</given-names></name><name><surname>Ribeiro</surname><given-names>A</given-names></name></person-group><article-title>In vitro transcriptional induction of the human apolipoprotein A-II gene by glucose</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>672</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">14988251</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.53.3.672</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castellani</surname><given-names>LW</given-names></name><name><surname>Goto</surname><given-names>AM</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group><article-title>Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>643</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">11246886</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.50.3.643</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Castellani</surname><given-names>LW</given-names></name><name><surname>Warden</surname><given-names>CH</given-names></name><name><surname>Puppione</surname><given-names>DL</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group><article-title>Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice</article-title><source>J Biol Chem</source><year>1993</year><volume>268</volume><fpage>20676</fpage><lpage>20682</lpage><pub-id pub-id-type="pmid">8376417</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warden</surname><given-names>CH</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Qiao</surname><given-names>JH</given-names></name><name><surname>Castellani</surname><given-names>LW</given-names></name><name><surname>Lusis</surname><given-names>AJ</given-names></name></person-group><article-title>Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II</article-title><source>Science</source><year>1993</year><volume>261</volume><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">8332912</pub-id><pub-id pub-id-type="doi">10.1126/science.8332912</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname><given-names>W</given-names></name><name><surname>Breslow</surname><given-names>JL</given-names></name></person-group><article-title>Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>14788</fpage><lpage>14794</lpage><pub-id pub-id-type="pmid">8962133</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.25.14788</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elbein</surname><given-names>SC</given-names></name><name><surname>Chu</surname><given-names>W</given-names></name><name><surname>Ren</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hemphill</surname><given-names>C</given-names></name><name><surname>Hasstedt</surname><given-names>SJ</given-names></name></person-group><article-title>Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance</article-title><source>Diabetologia</source><year>2002</year><volume>45</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">12136402</pub-id><pub-id pub-id-type="doi">10.1007/s00125-002-0850-5</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sladek</surname><given-names>R</given-names></name><name><surname>Rocheleau</surname><given-names>G</given-names></name><name><surname>Rung</surname><given-names>J</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Serre</surname><given-names>D</given-names></name><name><surname>Boutin</surname><given-names>P</given-names></name><name><surname>Vincent</surname><given-names>D</given-names></name><name><surname>Belisle</surname><given-names>A</given-names></name><name><surname>Hadjadj</surname><given-names>S</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Heude</surname><given-names>B</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name><name><surname>Prentki</surname><given-names>M</given-names></name><name><surname>Posner</surname><given-names>BI</given-names></name><name><surname>Balding</surname><given-names>DJ</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Polychronakos</surname><given-names>C</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>A genome-wide association study identifies novel risk loci for type 2 diabetes</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">17293876</pub-id><pub-id pub-id-type="doi">10.1038/nature05616</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><article-title>Report of the expert committee on the diagnosis and classification of diabetes mellitus</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>S5</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">12502614</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hercberg</surname><given-names>S</given-names></name><name><surname>Preziosi</surname><given-names>P</given-names></name><name><surname>Briancon</surname><given-names>S</given-names></name><name><surname>Galan</surname><given-names>P</given-names></name><name><surname>Triol</surname><given-names>I</given-names></name><name><surname>Malvy</surname><given-names>D</given-names></name><name><surname>Roussel</surname><given-names>AM</given-names></name><name><surname>Favier</surname><given-names>A</given-names></name></person-group><article-title>A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study &#x02013; design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants</article-title><source>Control Clin Trials</source><year>1998</year><volume>19</volume><fpage>336</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">9683310</pub-id><pub-id pub-id-type="doi">10.1016/S0197-2456(98)00015-4</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkau</surname><given-names>B</given-names></name></person-group><article-title>[An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]</article-title><source>Rev Epidemiol Sante Publique</source><year>1996</year><volume>44</volume><fpage>373</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">8927780</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Cherny</surname><given-names>SS</given-names></name><name><surname>Sham</surname><given-names>PC</given-names></name></person-group><article-title>Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">12499305</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/19.1.149</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jurinke</surname><given-names>C</given-names></name><name><surname>Boom</surname><given-names>D van den</given-names></name><name><surname>Cantor</surname><given-names>CR</given-names></name><name><surname>Koster</surname><given-names>H</given-names></name></person-group><article-title>Automated genotyping using the DNA MassArray technology</article-title><source>Methods in Molecular Biology</source><year>2002</year><volume>187</volume><fpage>179</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">12013745</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Scott</surname><given-names>L</given-names></name><name><surname>Saxena</surname><given-names>R</given-names></name><name><surname>Voight</surname><given-names>B</given-names></name><collab>for the DIAGRAM Consortium</collab></person-group><article-title>Meta-analysis of genome-wide association data and large-scale replication identifies several additional susceptibility loci for type 2 diabetes</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><fpage>638</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">18372903</pub-id><pub-id pub-id-type="doi">10.1038/ng.120</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>R</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Roix</surname><given-names>JJ</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Hughes</surname><given-names>TE</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Bengtsson Bostrom</surname><given-names>K</given-names></name><name><surname>Isomaa</surname><given-names>B</given-names></name><name><surname>Lettre</surname><given-names>G</given-names></name><name><surname>Lindblad</surname><given-names>U</given-names></name><name><surname>Lyon</surname><given-names>HN</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Newton-Cheh</surname><given-names>C</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Orho-Melander</surname><given-names>M</given-names></name><name><surname>Rastam</surname><given-names>L</given-names></name><name><surname>Speliotes</surname><given-names>EK</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Guiducci</surname><given-names>C</given-names></name><name><surname>Berglund</surname><given-names>A</given-names></name><name><surname>Carlson</surname><given-names>J</given-names></name><name><surname>Gianniny</surname><given-names>L</given-names></name><name><surname>Hackett</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>L</given-names></name><name><surname>Holmkvist</surname><given-names>J</given-names></name><name><surname>Laurila</surname><given-names>E</given-names></name><name><surname>Sjogren</surname><given-names>M</given-names></name><name><surname>Sterner</surname><given-names>M</given-names></name><name><surname>Surti</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Tewhey</surname><given-names>R</given-names></name><name><surname>Blumenstiel</surname><given-names>B</given-names></name><name><surname>Parkin</surname><given-names>M</given-names></name><name><surname>Defelice</surname><given-names>M</given-names></name><name><surname>Barry</surname><given-names>R</given-names></name><name><surname>Brodeur</surname><given-names>W</given-names></name><name><surname>Camarata</surname><given-names>J</given-names></name><name><surname>Chia</surname><given-names>N</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name><name><surname>Gibbons</surname><given-names>J</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Healy</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>K</given-names></name><name><surname>Gates</surname><given-names>C</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Gage</surname><given-names>D</given-names></name><name><surname>Nizzari</surname><given-names>M</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Chirn</surname><given-names>GW</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Parikh</surname><given-names>H</given-names></name><name><surname>Richardson</surname><given-names>D</given-names></name><name><surname>Ricke</surname><given-names>D</given-names></name><name><surname>Purcell</surname><given-names>S</given-names></name></person-group><article-title>Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>1331</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">17463246</pub-id><pub-id pub-id-type="doi">10.1126/science.1142358</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>Bmj</source><year>2003</year><volume>327</volume><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id></citation></ref><ref id="B23"><citation citation-type="book"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group><source>R: A Language and Environment for Statistical Computing</source><year>2007</year><publisher-name>Vienna, Austria: R Foundation for Statistical Computing</publisher-name></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Bonnycastle</surname><given-names>LL</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Duren</surname><given-names>WL</given-names></name><name><surname>Erdos</surname><given-names>MR</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><name><surname>Chines</surname><given-names>PS</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Prokunina-Olsson</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>CJ</given-names></name><name><surname>Swift</surname><given-names>AJ</given-names></name><name><surname>Narisu</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Pruim</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Conneely</surname><given-names>KN</given-names></name><name><surname>Riebow</surname><given-names>NL</given-names></name><name><surname>Sprau</surname><given-names>AG</given-names></name><name><surname>Tong</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>PP</given-names></name><name><surname>Hetrick</surname><given-names>KN</given-names></name><name><surname>Barnhart</surname><given-names>MW</given-names></name><name><surname>Bark</surname><given-names>CW</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Watkins</surname><given-names>L</given-names></name><name><surname>Xiang</surname><given-names>F</given-names></name><name><surname>Saramies</surname><given-names>J</given-names></name><name><surname>Buchanan</surname><given-names>TA</given-names></name><name><surname>Watanabe</surname><given-names>RM</given-names></name><name><surname>Valle</surname><given-names>TT</given-names></name><name><surname>Kinnunen</surname><given-names>L</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Bergman</surname><given-names>RN</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name></person-group><article-title>A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>1341</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">17463248</pub-id><pub-id pub-id-type="doi">10.1126/science.1142382</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Elliott</surname><given-names>KS</given-names></name><name><surname>Lango</surname><given-names>H</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Perry</surname><given-names>JR</given-names></name><name><surname>Rayner</surname><given-names>NW</given-names></name><name><surname>Freathy</surname><given-names>RM</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Shields</surname><given-names>B</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Groves</surname><given-names>CJ</given-names></name><name><surname>Harries</surname><given-names>LW</given-names></name><name><surname>Marchini</surname><given-names>JL</given-names></name><name><surname>Owen</surname><given-names>KR</given-names></name><name><surname>Knight</surname><given-names>B</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Morris</surname><given-names>AD</given-names></name><name><surname>Doney</surname><given-names>AS</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name></person-group><article-title>Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>1336</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">17463249</pub-id><pub-id pub-id-type="doi">10.1126/science.1142364</pub-id></citation></ref></ref-list></back></article> 